Resources » Reference Databases » Citations Database

For each citation that was shared on social media (LinkedIn, Facebook, or Twitter) with the “@GenScript” tag, the author will be rewarded with a $10 Amazon gift card or 2,000 GS points.

HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations

Mol Cancer Ther. 2022-07; 
Yong Du, Yongfeng Chen, Yuxia Wang, Jinju Chen, Xiaorong Lu, Li Zhang, Yan Li, Zhaofu Wang, Guozhong Ye, George Zhang
Products/Services Used Details Operation
Protein and Antibody Isolation … Boiled 11 samples were loaded into bis-tris polyacrylamide gels (4–12%; Genscript, #M00654). Target proteins were transferred to nitrocellulose membranes which were probed with … Get A Quote

Abstract

The EGFR C797S mutation is the most common on-target resistance mechanism to osimertinib in patients with advanced non-small cell lung cancer (NSCLC). Currently there are no effective treatment options for patients with NSCLC harboring EGFR C797S triple mutants (Del19/T790M/C797S and L858R/T790M/C797S). Herein, we report an orally bioavailable EGFR PROTAC, HJM-561, which selectively degrades the EGFR C797S-containing triple mutants. HJM-561 potently inhibits the proliferation of Del19/T790M/C797S and L858R/T790M/C797S Ba/F3 cells while sparing cells expressing wild-type EGFR. Oral administration of HJM-561 shows robust antitumor activity in EGFR Del19/T790M/C797S-driven Ba/F3 CDX and PDX models that were resist... More

Keywords

Article Link >

Most Popular Services

Homology-Directed Repair (HDR) Knock-in Templates
CRISPR Cas9 Single guide RNA (sgRNA) and Ribonucleoprotein (RNP)
Plasmid DNA Preparation Service
Mammalian CHO Expression Service